Incyte CORP
Forward trial catalysts linked to INCY
CSA tracks 2 forward catalysts for Incyte CORP across 1 asset, spanning Phase 3. The nearest is a readout expected Dec 26, 2026 (day precision). Confidence across its tracked catalysts breaks down as 2 medium. Tracked indications include NonSegmental Vitiligo, Hidradenitis Suppurativa (HS).
INCY in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Incyte CORP has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
4 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| povorcitinib | NCT06113445 | Phase 3 | Active, not recruiting | 2026-02-24 | Experimental | Incyte Corporation | NonSegmental Vitiligo |
| povorcitinib | NCT06113471 | Phase 3 | Active, not recruiting | 2026-03-17 | Experimental | Incyte Corporation | NonSegmental Vitiligo |
| povorcitinib | NCT06212999 catalyst | Phase 3 | Active, not recruiting | 2026-12-26 | Experimental | Incyte Corporation | Hidradenitis Suppurativa (HS) |
| povorcitinib | NCT06855498 catalyst | Phase 3 | Recruiting | 2028-02-28 | Experimental | Incyte Corporation | Hidradenitis Suppurativa (HS) |
Every trial the CSA sample links to INCY's tracked assets.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →